Therapy/Class: Antibacterial Agent / Oxazolidinone Class
Spectrum of Coverage:
- Aerobic & facultative Gram-positive microorganisms
- Enterococcus faecium (vancomycin-resistant strains only)
- Staphylococcus aureus (including methicillin-resistant strains)
- Streptococcus agalactiae
- Streptococcus pneumoniae (including multi-drug resistant isolates [MDRSP]
- Streptococcus pyogen
- Aerobic & facultative Gram-negative microorganisms
- Pasteurella multocida
Mechanism of Action:
- Inhibits bacterial protein synthesis
- Bacteriostatic against Enterococci&StaphylococciStrains whereas, bactericidal against Streptococci& majority of bacterial strain
- Binds to 23S ribosomal RNA of the 50S subunit & prevents the formation of a functional 70S initiation complex which is an essential component of the bacterial translation process.
Indications:
- Vancomycin-Resistant Enterococcus faecium infections
- Nosocomial pneumonia
- Complicated skin & skin structure infections, including diabetic foot infections, withoutconcomitant osteomyelitis
- Uncomplicated skin & skin structure infections
- Community-acquired pneumonia
Dosage & Administration:
| Infection* | Pediatric Patients (Birth through 11 Years of Age) | Adolescents & Adults (12 Years & Older) | Recommended Duration of Treatment (Consecutive Days) |
| Nosocomial pneumonia | 10 mg/kg every 8 hours | 600 mg 12 hours | 10 to 14 |
| Community-acquired pneumonia, including concurrent bacteremia | |||
| Complicated skin and skin structure infections | |||
| Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia | 10 mg/kg every 8 hours | 600 mg every 12 hours | 14 to 28 |
| Uncomplicated skin and skin structure infections | <5 yrs: 10 mg/kg every 8 hours 5-11 yrs: 10 mg/kg every 12 hours | Adolescents: 600 mg every 12 hours Adults: 400 mg every 12 hours | 10 to 14 |
HOW SUPPLIED: 30 ml Oral Dry Syrup is available in Dry Powdered form with Sterile Water.
References:
Fine MJ, Auble TE, Yealy DM, et al. A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia. The New England Journal of Medicine. 1997;336 (4):243-250.
